Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study
modelling the population-level health and economic impacts of introducing Vaccae vaccination to inform policy-makers in China
research
Is neglect of self-clearance biasing TB vaccine impact estimates?
exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India
The full value of vaccine assessments concept—current opportunities and recommendations
Building on the success of the recent applications of the FVVA framework, we see important new opportunities to maximize the future utility of FVVAs to country and global stakeholders and provide a proof-of-concept for analyses in other areas of disease control and prevention.
ACEITar: Evaluation of the acceptability of new and repurposed tuberculosis vaccines in Mozambique
This is a mixed-methods study collecting information on willingness to receive a new TB vaccine among adolescents, their caretakers, and adults in Mozambique, a high TB burden country, to assess potential barriers to high uptake of new TB vaccines.
What do people want?
Investigate current TB prevention modalities vs vaccine. We lack understanding of preferences and trade offs people would be willing to make across a spectrum of issues related to study design, type of vaccines, how they are given, how often, where they are given, to whom, efficacy estimates and side effects etc.
Country and target population prioritization
Evidence-based matrixing approach to identify priority countries and target populations through an iterative process, engaging a set of diverse stakeholders
Modelling the health and economic impacts of M72/AS01E vaccination and BCG-revaccination: estimates for South Africa
we used a mathematical model to estimate the health impact and cost-effectiveness of M72/AS01E and BCG-revaccination in South Africa under a range of vaccine characteristics and delivery assumptions
The impact of alternative delivery strategies for novel tuberculosis vaccines in low-income and middle-income countries: a modelling study
We estimated the impact of novel tuberculosis vaccines in low-income and middle-income countries (LMICs) in several delivery scenarios.
The cost and cost-effectiveness of novel tuberculosis vaccines in low- and middle-income countries: A modeling study
We assessed future costs, cost-savings, and cost-effectiveness of introducing novel TB vaccines in low- and middle-income countries (LMICs) for a range of product characteristics and delivery strategies.